Biosynthetic musk & aromas

Musk is the fixative and sensual base note of fine perfumery, historically sourced from musk-deer glands (now restricted for animal-welfare and conservation reasons) or from nitro-musk and polycyclic-musk chemistry, both of which face REACH restrictions in the EU over environmental persistence and bioaccumulation. In 2026 the confirmed commercial activity centers on established macrocyclic ketone and lactone chemistries rather than a dedicated engineered-yeast fermentation product: Givaudan markets Velvione, a 16-membered macrocyclic musk ketone described in trade literature as carrying a warm, powdery, animalic note; DSM-Firmenich continues its Exaltolide brand, a macrocyclic-lactone musk dating to Firmenich’s classic perfumery-materials portfolio; IFF unveiled its Orionide Oliffac clean-musk line at SIMPPAR 2026, positioned as a “modern clean musk” with a soft, natural-leaning, low-weight diffusion profile; and in China, Beijing Lianxin Pharmaceutical (founded 1999, co-established by the Institute of Materia Medica of the Chinese Academy of Medical Sciences and three other state-linked shareholders) manufactures a state-designated Class-1 new-drug “artificial musk” substitute for musk-deer secretions used in traditional-medicine formulations, recognized with a National Science and Technology Progress Award. A dedicated engineered-yeast fermentation route to macrocyclic musks — omega-hydroxy fatty-acid production via oleaginous yeast followed by lipase-catalyzed macrocyclization — appears in patent-application literature (“biotechnological production of macrocyclic lactones,” filed 2022, published 2026) but no confirmed commercial company was identified as its assignee or commercial operator in 2026 sourcing.

The key directions of biosynthetic musk & aromas are:

1. Macrocyclic musk ketone production (Macrocyclic Musk Ketone Production): Givaudan’s Velvione, a 16-membered macrocyclic musk ketone marketed as a modern, non-nitro alternative carrying an animalic-powdery character.
2. Established macrocyclic lactone branding (Macrocyclic Lactone Musk Branding): DSM-Firmenich’s Exaltolide, a long-standing macrocyclic-lactone musk brand from Firmenich’s classic perfumery-materials heritage.
3. Clean-musk reformulation (Clean Musk Fragrance Formulation): IFF’s Orionide Oliffac, unveiled at SIMPPAR 2026, positioned as a soft, natural-leaning musk with enhanced diffusion and substantivity without added olfactive weight.
4. TCM artificial-musk substitute manufacturing (TCM Artificial Musk Substitute Manufacturing): Beijing Lianxin Pharmaceutical’s state-designated Class-1 new-drug artificial musk, replacing endangered musk-deer secretions in traditional-medicine formulations under NMPA oversight.

Sectoral value chain#

[macrocyclic ketone/lactone precursors or musk-deer-secretion-analog chemistry] ──> [chemical macrocyclization or multi-component synthesis]
                                                                                                │
                                                                                (crude musk material)
                                                                                                │
                                                                                                ▼
[fine-perfumery or pharmaceutical-grade musk] <─── [purification and olfactive/pharmacopeial QC] <───┘
                                                                                                │
                                                                                                ▼
                                                [fine perfumery, personal care, traditional-medicine formulations]

Value chain levels#

Cross-cutting technologies of the sector:

• Macrocyclic ring chemistry (Macrocyclic Musk Ketone Production / Macrocyclic Lactone Musk Branding): the 15-17-membered ring structures (Velvione’s 16-membered ketone, Exaltolide’s macrocyclic lactone) shared by the dominant non-nitro musk chemistries.
• Clean-label reformulation (Clean Musk Fragrance Formulation): IFF’s Orionide Oliffac positioning around a “natural-leaning,” low-weight olfactive profile, reflecting the sector-wide move away from nitro- and polycyclic-musk restricted chemistries.
• State-designated substitute drug manufacturing (TCM Artificial Musk Substitute Manufacturing): Beijing Lianxin’s NMPA-certified Class-1 new-drug status for artificial musk, a distinct regulatory and technical pathway from fragrance-grade musk chemistry.

The stack spans established macrocyclic ring chemistry for fragrance-grade musk and a distinct pharmaceutical-substitute chemistry for traditional-medicine use, rather than a dedicated fermentation platform.

1. Macrocyclic ketone/lactone ring chemistry (Macrocyclic Musk Ketone Production / Macrocyclic Lactone Musk Branding):
   • Givaudan’s Velvione is built on a 16-membered macrocyclic ketone ring, positioned as a modern successor to legacy nitro-musks without their environmental-persistence liabilities.
   • DSM-Firmenich’s Exaltolide is a macrocyclic-lactone musk from the same broad chemistry family, differentiated by ring size and functional group (lactone vs. ketone).
2. Clean-label olfactive reformulation (Clean Musk Fragrance Formulation):
   • IFF’s Orionide Oliffac, unveiled at SIMPPAR 2026, is positioned around enhanced diffusion and substantivity “without adding weight,” reflecting a sector-wide push toward natural-leaning, low-intensity musk profiles.
3. State-designated substitute drug technology (TCM Artificial Musk Substitute Manufacturing):
   • Beijing Lianxin’s artificial-musk substitution technology replicates the composition of natural musk-deer secretions for traditional-medicine formulations, certified as a Class-1 new drug and recognized with a National Science and Technology Progress Award — a technically and regulatorily distinct achievement from fragrance-grade macrocyclic musk chemistry.
   • A separate engineered-yeast route (omega-oxidation of fatty acids via oleaginous yeast, followed by lipase-catalyzed macrocyclization) appears in patent-application literature filed 2022 and published 2026, but remains unconfirmed against a named commercial operator.